Author

J. Triscott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

M. A. Rubin· 2 shared M. Bolis· 2 shared S. Piscuoglio· 2 shared Y. Chen· 2 shared A. Augspach· 1 shared A. Benjak· 1 shared A. King-Yung Leung· 1 shared A. Naveed· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. A. Rubin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

P. D. Thienger, I. Paassen, X. Yao, P. D. Rubin, M. Lehner, N. Lillis, A. Benjak, S. Shah, A. King-Yung Leung, S. de Brot, A. Naveed, B. Daniel, M. Shi, J. Tremblay, J. Triscott, , M. A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

bioRxiv · Mar 24, 2024Cancer Biology

Minor intron splicing efficiency increases with the development of lethal prostate cancer

A. Augspach, K. Drake, L. Roma, E. Qian, S. R. Lee, D. Clarke, S. Kumar, M. Jaquet, J. Gallon, M. Bolis, J. Triscott, J. A. Galvan, Y. Chen, G. Thalmann, M. Kruithof-de Julio, , M. A. Rubin

The paper shows that minor intron splicing efficiency increases in castration-resistant prostate cancer and that inhibiting the minor spliceosome reduces tumor burden.

bioRxiv · Dec 9, 2021 · PreprintCancer Biology